Home Multimedia Exclusive Videos Exclusive VideosMultimedia ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients Sunday, January 1, 2017 Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit FLT3 in relapsed/refractory AML patients. Advertisement Recent Articles Pilot Study Finds Remote Monitoring of Patients Undergoing Chemotherapy Feasible Tuesday, October 19, 2021 Using technology to monitor outpatients undergoing cancer treatments at home was feasible and led to improvements in care, according to results of a pilot... Could APP-Led Quality and Safety Grand Rounds Improve Patient Outcomes? Tuesday, October 19, 2021 Grand rounds provide an opportunity for oncology advanced practice providers (APPs) to discuss quality and safety across disciplines and may have positive effects on... Classical Hematology: A Specialty in Decline? Monday, October 18, 2021 As workforce shortages persist, this ancient art is undergoing a modern renaissance. Two factors influenced Alfred Ian Lee, MD, PhD, to specialize in classical hematology.... Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell... Monday, October 18, 2021 A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell... New Prognostic Model Outperforms Established Predictive Models in MDS Monday, October 18, 2021 In a study published in the Journal of Clinical Oncology, researchers reported that a newly developed personalized prediction model comprising clinical and genomic data... Current Issue October 2021, Volume 7, Issue 12 Friday, October 1, 2021 This issue tells the long story of drug shortages, demystifies transfusion services, and more.